CJC-1295 (No Dac)

CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). Supplied as a lyophilized powder, it is intended for in-vitro laboratory research into GHRH-receptor signaling and growth-hormone axis biology.

Molecular Profile

• CAS Number863288-34-0
• Molecular Weight3,367.9 g/mol
• Molecular FormulaC₁₅₂H₂₅₂N₄₄O₄₂
• SequenceModified GRF(1-29), 29 aa
• Purity≥99.6% (HPLC-MS/MS)
• FormatLyophilized white powder
• Storage−20°C, desiccated
• ReconstitutionSterile bacteriostatic water

Research Context

Modified GRF(1-29) is studied in the preclinical literature as a GHRH-receptor agonist used to investigate somatotroph signaling and the growth-hormone / IGF-1 axis in laboratory models.

Quality Assurance

Every lot is independently tested for identity and purity by SideChain Analytics (HPLC-MS/MS), and a Certificate of Analysis is available for each batch. Produced and shipped from within Canada.

Available exclusively for in-vitro laboratory research. Not a drug, natural health product, or food; not for human or veterinary use, and not evaluated for diagnostic or therapeutic application. Researchers are responsible for compliance with all applicable regulations.

• CompoundCJC-1295 (No Dac)
• Strength10 mg per vial
• Pack sizes1 vial · 3 pack · 6 pack
• AppearanceLyophilized white powder
• Storage−20°C, protect from light
• VerificationThird-party HPLC-MS/MS (SideChain Analytics)
• OriginNorth American made · ships from Canada

Reported in preclinical, in-vitro literature in the following research areas:

• GHRH-receptor signaling
• GH / IGF-1 axis research
• Pituitary somatotroph models
• Peptide-analog pharmacology

These are areas of laboratory investigation only. No physiological, clinical, or health outcome is claimed or implied for any use of this compound.

As a GHRH analog, CJC-1295 (no DAC) has been reported to bind the GHRH receptor and stimulate growth-hormone-releasing signaling in preclinical models. The ‘no DAC’ form lacks the Drug Affinity Complex modification, giving it a shorter reported half-life than the DAC variant.